C21orf33 (ES1 protein homolog, mitochondrial) is a 25 kDa protein overexpressed in fetal Down syndrome brain tissue . Key features include:
Function: Member of the DJ-1/PfpI family, involved in metabolic pathways
Clinical Relevance: Potential biomarker for mitochondrial dysfunction studies
Both antibodies detect a 25 kDa band in human cell lines (e.g., HepG2, HeLa) . The monoclonal antibody (ab181366) shows enhanced specificity for immunoprecipitation and immunofluorescence .
ab181366 demonstrates robust staining in paraffin-embedded human liver and heart tissues at 1:50 dilution, requiring heat-mediated antigen retrieval .
Storage: Both antibodies require storage at -20°C with minimized freeze-thaw cycles .
Buffer Compatibility: Polyclonal antibodies use PBS with 50% glycerol, while monoclonal variants require optimized buffers for stability .
Cross-Reactivity: Confirmed specificity for human samples; non-human reactivity remains untested .
C21orf33 antibodies enable mitochondrial protein localization studies in Down syndrome models .
Framework mutations (e.g., VRC01gl Q39L + comL) improve binding affinity by 4-fold in related antibody systems, suggesting optimization strategies for future C21orf33 assays .
Multi-application validation (WB + IHC-P) reduces off-target risks in complex samples .
No peer-reviewed studies explicitly using a C21orf33 "antibody pair" were identified.
Structural stability data (e.g., aggregation propensity under stress) remain undocumented for these antibodies.
Future work could explore combinatorial use of polyclonal and monoclonal antibodies for enhanced signal-to-noise ratios in low-abundance mitochondrial protein detection.